

FP00503 US

1040
#6
ms
8/20/02

I hereby certify that this correspondence is being deposited with the United States Postal Service in first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on 25 July 2002.

Carolyn C. CairesPrinted: Carolyn C. CairesCOPY OF PAPERS
ORIGINALLY FILED

RECEIVED

AUG 06 2002

TECH CENTER 1800 2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Findell and Marinkovich

Assignee: FibroGen, Inc. and
The Board of Trustees of The
Leland Stanford Junior University

Title: METHODS OF AFFECTING LAMININ 5 PROCESSING

Serial No. 09/854,188

Filing Date: 11 May 2001

Examiner: Not yet assigned

Group Art Unit: 1646

Assistant Commissioner for Patents
Washington, D.C. 20231SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.97(c)

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97, and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants" (PTO Form 1449). Applicants reserve the right to antedate any reference in accordance with standard procedure.

Each item of the information contained in the information disclosure statement was cited in an International Search Report prepared by the International Searching Authority of the counterpart PCT application of the above-identified U.S. application not more than three month prior to the filing of this statement. For your reference, a copy of the International Search Report is also being provided.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the present application. In addition, this submission is understood to complement the results of the Examiner's own independent search. Citation of the


documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI or other report included on the attached list may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the PTO Form 1449 be returned to Applicants.

If there are any questions regarding this communication, please call the undersigned at 650-866-7200.

Applicants believe that no fee is due with this communication. If, however, the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge any necessary fees to Deposit Account No. 50-0811. **This form is enclosed in duplicate.**

Respectfully submitted,
FibroGen, Inc.

DATE: 25 July 2002



Christopher Turner, Ph.D.
Reg. No. 45,167

FibroGen, Inc.
225 Gateway Boulevard
South San Francisco CA 94080
Main: 650-866-7200
Direct: 650-866-7265
Facsimile: 650-866-7204